Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CellOrigin Biotech logo — CellOrigin Biotech, a company committed to iPSC-derived inna...

CellOrigin Biotech

CellOrigin Biotech, a company committed to iPSC-derived innate immune cell therapeutics

Founded 2018 China Hangzhou, China 4 employees Series Unknown Total: $100.00M Biotechnology

General Information

Company Name CellOrigin Biotech
Founded Year 2018
Location China Hangzhou, China +1
Employees 4
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when CellOrigin Biotech moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CellOrigin Biotech

CellOrigin Biotech is a biotech company established in 2018 with a dedication to developing iPSC-derived innate immune cell therapeutics. Dr. Jin Zhang, the scientific co-founder, brings valuable experience from the Boston Children’s Hospital and Harvard Medical School. The company's focus on iPSC-derived innate immune cells for cancer immunotherapies led to the groundbreaking development of iPSC-derived CAR-macrophages (CAR-iMac). CellOrigin Biotech currently possesses proprietary technologies for iPSC-derived CAR-Macrophage, collaborating with leading research groups at Harvard and MIT to harness the full potential of iPSC-derived immune cells. They aim to deliver more effective, universal, and safe immune cell products, particularly for solid tumor patients. The company has initiated investigator-initiated trials at the First Hospital of Zhejiang University and holds core proprietary technology platforms and patents for engineered macrophages from pluripotent stem cells. Their latest funding round, a Venture Round investment on 21 September 2023, involved Goldport Capital and Yuhang state Investment. Currently headquartered in China, CellOrigin Biotech is actively expanding its reach globally, with patent authorization processes underway in the US, Australia, South Africa, and other locations.

Taxonomy: Biotech, Innate immune cells, iPSC-derived, Cancer immunotherapies, Genome engineering, Synthetic biology, CAR-Macrophages, Solid tumors, Clinical trials, Stem cell research, Cancer treatment, Therapeutics, Medical technology, Intellectual property, Research collaboration

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 2 •••• •••• 21 Sep 2023
Venture Round •••••• 4
Investor Investor Investor Investor
29 Mar 2022
Venture Round •••••• 2
Investor Investor
20 Jul 2021

CellOrigin Biotech Alternatives & Competitors

CellOrigin Biotech vs
Cytovia Therapeutics
Cytovia Therapeutics United States

We empower Natural Killer cells to fight cancer through stem cell engineering and multispecific anti...

Unknown
6 employees
Biotechnology, Life Sciences
CellOrigin Biotech vs
BrainXell
BrainXell United States

Human iPSC-Derived Neurons for CNS Drug Discovery

43 employees
CellOrigin Biotech vs
Cell BioEngines, Inc
Cell BioEngines, Inc United States

‘Off-the-Shelf’ Curative Cell Therapies

Pre Seed
3 employees
Biotechnology, Health and Wellness

FAQ About CellOrigin Biotech

CellOrigin Biotech, a company committed to iPSC-derived innate immune cell therapeutics
CellOrigin Biotech was founded in 2018.
CellOrigin Biotech is headquartered in Hangzhou, China.
CellOrigin Biotech operates in the following industries: Biotechnology.
CellOrigin Biotech has approximately 4 employees.
CellOrigin Biotech has completed 3 funding rounds, raising a total of $100.00M. The latest funding stage is Series Unknown.
Top alternatives and competitors to CellOrigin Biotech include Cytovia Therapeutics, BrainXell, Cell BioEngines, Inc, OSE Immunotherapeutics, T&RBiofab. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CellOrigin Biotech and Cytovia Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CellOrigin Biotech and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy